Phase II trial of AE 37 in patients with prostate cancer
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2015
At a glance
- Drugs AE 37 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 15 Oct 2015 According to a Generex Biotechnology media release, Antigen Express has entered into a Memorandum of Understanding with CompanDX to conduct this study. CompanDX has established a subsidiary, TumourVac, for the administration of the Phase II AE37 prostate cancer study.
- 03 Jan 2012 Generex intends to move ahead with this trial more rapidly than anticipated, according to a company media release.
- 06 Oct 2011 Antigen Express is continuing with plans for this trial, according to a company media release.